Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy

Cancer Research

Volumn 73, Issue 17, 2013, Pages 5391-5401

  Végran, Frédérique ^a,b   Mary, Romain ^a   Gibeaud, Anne ^a   Mirjolet, Céline ^a   Collin, Bertrand ^a,c   Oudot, Alexandra ^a   Charon Barra, Céline ^a   Arnould, Laurent ^a   Lizard Nacol, Sarab ^a   Boidot, Romain ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b Chu   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; PROCASPASE 8; STAUROSPORINE; SURVIVIN; SURVIVIN 3B; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DEPOLARIZATION; DRUG TOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE ESCAPE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; SOLID TUMOR; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOPRECIPITATION; INHIBITOR OF APOPTOSIS PROTEINS; KILLER CELLS, NATURAL; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84883484292     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0036     Document Type: Article

References (34)

1. Dutertre M, Vagner S, Auboeuf D. Alternative splicing and breast cancer. RNA Biol 2010;7:403-11.
2. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54. (Pubitemid 39446889)
3. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-8.
4. Ambrosini G, Adida C, Altieri DC. Anovel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21. (Pubitemid 27353455)
5. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102. (Pubitemid 30035627)
6. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004;314:902-7. (Pubitemid 38112885)
7. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.
8. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001;98:2091-100.
9. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34 (+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002;100:2463-71.
10. Jacob NK, Cooley JV, Shirai K, Chakravarti A. Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther 2012;5:7-20.
11. Végran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol 2005;27:1151-7.
12. Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007;26:290-7. (Pubitemid 46095740)
13. Boidot R, Végran F, Jacob D, Chevrier S, Cadouot M, Feron O, et al. The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene 2010;29:2577-84.
14. Végran F, Boidot R, Solary E, Lizard-Nacol S. A short caspase-3 isoform inhibits chemotherapy-induced apoptosis by blocking apoptosome assembly. PLoS ONE 2011;6:e29058.
15. Didelot C, Barberi-Heyob M, Bianchi A, Becuwe P, Mirjolet JF, Dauça M, et al. Constitutive NF-kappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines. Int J Radiat Oncol Biol Phys 2001;51:1354-1360. (Pubitemid 33116331)
16. Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat 2012;134:139-55.
17. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001;97:2886-95.
18. Trapani JA, Smyth MJ. Functional significance of the perforin/gran-zyme cell death pathway. Nat Rev Immunol 2002;2:735-47. (Pubitemid 37328714)
19. Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, et al. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem 2001;276:12060-7.
20. Heidemann SC, Chavez V, Landers CJ, Kucharzik T, Prehn JL, Targan SR. TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets. J Clin Immunol 2010;30:531-8.
21. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-88.
22. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87. (Pubitemid 28119121)
23. Aptsiauri N, Cabrera T, Garcia-Lora A, Garrido F. Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3-5, 2011. Cancer Immunol Immunother 2012;61:739-45.
24. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rödel F, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007;6:1502-9.
25. Sawai K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res 2010;18:541-7.
26. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssière JL, Petit PX, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181:1661-72.
27. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
28. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011;17:860-6.
29. Boidot R, Végran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009;23:285-91.
30. Végran F, Boidot R, Bonnetain F, Cadouot M, Chevrier S, Lizard-Nacol S. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma. Endocr Relat Cancer 2011;18:783-92.
31. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012;118:3128-34.
32. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012;23:968-73.
33. Holmes D. Cancer drug's survivin suppression called into question. Nat Med 2012;18:842-3.
34. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20. (Pubitemid 28551107)